Ratings Gland Pharma Limited

Equities

GLAND

INE068V01023

Market Closed - NSE India S.E. Other stock markets 07:43:52 2024-05-13 am EDT			5-day change	1st Jan Change
1,764 ^INR	+3.18%		+4.62%	-8.32%

May. 07	Gland Pharma Gets US FDA's Approval for Generic ALS Drug	MT
May. 07	Gland Pharma Gets US FDA's Approval for Generic Stem Cell Mobilizer Injection	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company returns high margins, thereby supporting business profitability.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 34.15 times its estimated earnings per share for the ongoing year.
The company's enterprise value to sales, at 4.66 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is not the most generous with respect to shareholders' compensation.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
GLAND PHARMA LIMITED	-8.32%	3.37B	B-
ELI LILLY AND COMPANY	+29.98%	684B	C+
NOVO NORDISK A/S	+30.34%	568B	B
JOHNSON & JOHNSON	-3.52%	361B	C+
MERCK & CO., INC.	+18.59%	329B	B-
ABBVIE INC.	+4.07%	284B	C+
ASTRAZENECA PLC	+16.21%	240B	B+
NOVARTIS AG	+9.66%	208B	B-
ROCHE HOLDING AG	-6.83%	200B	A+
AMGEN INC.	+7.09%	166B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes